Add this topic to your myFT Digest for news straight to your inbox
German biotech maintains guidance but prepares for fall in sales because of jab oversupply
Remuneration at the three big jab makers reflects surge in value of share options
German biotech plans to boost R&D spending by 50% as quarterly earnings beat forecasts
Johnson government announces plan after similar moves in Scotland and Wales
First human study of variant-specific jab by big western drugmaker could prompt shift in manufacturing
Hopes early warning system will give policymakers and vaccine producers more time to address health risks
Drugmakers set to take on GSK as they aim to replicate Covid jab success
Long the poor relation to Frankfurt, Mainz aims to cash in on ‘priceless advertising’ offered by biotech group
Preliminary research suggests two shots show significantly reduced effectiveness against new coronavirus variant
Drugmakers are stress-testing existing jabs while preparing new formulas
WHO says differing predictions from Oxford, BioNTech and Moderna are ‘premature’
Combating coronavirus could end up resembling a game of whack-a-mole
German biotech expects to hit €17bn in sales and produce 3bn jabs this year
Hesitancy high as regulators authorise BioNTech/Pfizer Covid-19 vaccine for 5 to 11 year olds
US expected to become first country to authorise vaccine for younger children
Rwanda and Senegal agreement a big step in plans to produce Covid jabs on the continent
Researchers emphasise that adverse events following Pfizer and AstraZeneca jabs are extremely rare
Results hailed as ‘important’ but duration of protection still unknown
Bullish projections show mRNA jab producers could generate more than $90bn in sales next year
Personalised cancer treatments are among those being developed using a technology once distrusted by big pharma
Ugur Sahin says the virus is very likely to mutate and evade immunity given by current jabs
Elderly and at-risk to be offered third dose of BioNTech/Pfizer Covid-19 jab under scaled-back plan
Joe Biden urges other wealthy countries to follow suit in a bid to boost access around the world
Companies say data provide ‘strong foundation’ to seek authorisation to vaccinate 5-11 age group
Executive signals intention to secure authorisation for infants as young as six months old
International Edition